Glomerulopathy Clinical Trials

2 recruiting

Glomerulopathy Trials at a Glance

10 actively recruiting trials for glomerulopathy are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Madrid, Ohtsu, and Barcelona. Lead sponsors running glomerulopathy studies include Novartis Pharmaceuticals, Omeros Corporation, and ADARx Pharmaceuticals, Inc..

Browse glomerulopathy trials by phase

Treatments under study

About Glomerulopathy Clinical Trials

Looking for clinical trials for Glomerulopathy? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glomerulopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glomerulopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

Chinese Adults With Kidney Disease

Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 1

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

C3 Glomerulopathy (C3G)
eleva GmbH39 enrolled16 locationsNCT07483827
Recruiting
Phase 3

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

C3 GlomerulopathyImmune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals225 enrolled50 locationsNCT03955445
Recruiting

Fabhalta Capsules Specified Drug-use Survey

C3 Glomerulopathy
Novartis Pharmaceuticals50 enrolled26 locationsNCT07156149
Recruiting
Phase 3

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Kidney DiseasesKidney Diseases, ChronicUrological Diseases+5 more
Novartis Pharmaceuticals220 enrolled6 locationsNCT06858319
Recruiting
Phase 2

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 GlomerulopathyIdiopathic Immune Complex-Mediated Glomerulonephritis
Omeros Corporation20 enrolled6 locationsNCT06209736
Recruiting
Phase 2

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

C3 GlomerulopathyDense Deposit DiseaseMembranoproliferative Glomerulonephritis+2 more
Region Skane30 enrolled4 locationsNCT04183101
Recruiting

Home Reported Outcomes in C3G Study

C3 Glomerulopathy
Novartis Pharmaceuticals100 enrolled1 locationNCT07029542
Recruiting

Clinical Phenotyping Resource and Biobank Core of the Michigan O'Brien Renal Center

Chronic Kidney DiseaseGlomerulopathy
University of Michigan1,800 enrolled5 locationsNCT01016613
Recruiting

National Registry of Rare Kidney Diseases

Denys-Drash SyndromeTuberous SclerosisAutosomal Recessive Polycystic Kidney Disease+81 more
UK Kidney Association35,000 enrolled1 locationNCT06065852